Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Nobufumi Sekino, Ph.D., M.D.

Title
Institution
Department
Address
Phone
Fax

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Sekino N, Kano M, Sakata H, Murakami K, Toyozumi T, Matsumoto Y, Ryuzaki T, Ikeda J, Ota M, Matsubara H. Caspase recruitment domain family member 9 expression is a promising biomarker in esophageal squamous cell carcinoma. Ann Gastroenterol Surg. 2020 Mar; 4(2):135-141. PMID: 32258978.
    Citations:    
  2. Shiraishi T, Kano M, Sakata H, Murakami K, Toyozumi T, Sekino N, Okada K, Kamata T, Ryuzaki T, Matsubara H. [Successful Treatment of Gastric Cancer with Conversion Surgery after Nivolumab Treatment-A Case Report]. Gan To Kagaku Ryoho. 2019 Oct; 46(10):1614-1616. PMID: 31631152.
    Citations:    
  3. Kamata T, Kano M, Takahashi M, Murakami K, Sakata H, Toyozumi T, Sekino N, Yokoyama M, Okada K, Shiraishi T, Ryuzaki T, Matsubara H. [Development of TP53-Targeted Treatment in Esophageal Squamous Cell Carcinoma Using Cancer Genomic Profiling Test]. Gan To Kagaku Ryoho. 2019 Oct; 46(10):1608-1610. PMID: 31631150.
    Citations:    
  4. Hoshino I, Takahashi M, Akutsu Y, Murakami K, Matsumoto Y, Suito H, Sekino N, Komatsu A, Iida K, Suzuki T, Inoue I, Ishige F, Iwatate Y, Matsubara H. Genome-wide ChIP-seq data with a transcriptome analysis reveals the groups of genes regulated by histone demethylase LSD1 inhibition in esophageal squamous cell carcinoma cells. Oncol Lett. 2019 Jul; 18(1):872-881. PMID: 31289565.
    Citations:    
  5. Sekino N, Kano M, Matsumoto Y, Sakata H, Murakami K, Toyozumi T, Otsuka R, Yokoyama M, Shiraishi T, Okada K, Kamata T, Ryuzaki T, Matsubara H. The Antitumor Effects of Metformin on Gastric Cancer In Vitro and on Peritoneal Metastasis. Anticancer Res. 2018 Nov; 38(11):6263-6269. PMID: 30396946.
    Citations:    
  6. Kano M, Miyauchi H, Matsushita K, Murakami K, Toyozumi T, Hayano K, Otsuka R, Takahashi M, Sekino N, Shiraishi T, Arai M, Takiguchi Y, Matsubara H. [Dawn of Cancer Clinical Sequencing in Chiba University Hospital]. Gan To Kagaku Ryoho. 2018 Oct; 45(10):1463-1465. PMID: 30382046.
    Citations:    
  7. Sekino N, Kano M, Matsumoto Y, Sakata H, Akutsu Y, Hanari N, Murakami K, Toyozumi T, Takahashi M, Otsuka R, Yokoyama M, Shiraishi T, Okada K, Hoshino I, Iida K, Akimoto AK, Matsubara H. Antitumor effects of metformin are a result of inhibiting nuclear factor kappa B nuclear translocation in esophageal squamous cell carcinoma. Cancer Sci. 2018 Apr; 109(4):1066-1074. PMID: 29396886.
    Citations:    
  8. Akutsu Y, Murakami K, Kano M, Toyozumi T, Matsumoto Y, Takahashi M, Otsuka R, Sekino N, Yokoyama M, Shiraishi T, Matsubara H. The concentration of programmed cell death-ligand 1 in the peripheral blood is a useful biomarker for esophageal squamous cell carcinoma. Esophagus. 2018 04; 15(2):103-108. PMID: 29892935.
    Citations:    
  9. Otsuka R, Akutsu Y, Sakata H, Hanari N, Murakami K, Kano M, Toyozumi T, Takahashi M, Matsumoto Y, Sekino N, Yokoyama M, Okada K, Shiraishi T, Komatsu A, Iida K, Matsubara H. ZNF750 Expression Is a Potential Prognostic Biomarker in Esophageal Squamous Cell Carcinoma. Oncology. 2018; 94(3):142-148. PMID: 29216641.
    Citations:    
  10. Otsuka R, Akutsu Y, Sakata H, Hanari N, Murakami K, Kano M, Takahashi M, Matsumoto Y, Sekino N, Yokoyama M, Iida K, Matsubara H. ZNF750 Expression as a Novel Candidate Biomarker of Chemoradiosensitivity in Esophageal Squamous Cell Carcinoma. Oncology. 2017; 93(3):197-203. PMID: 28558382.
    Citations:    
  11. Hoshino I, Akutsu Y, Murakami K, Akanuma N, Isozaki Y, Maruyama T, Toyozumi T, Matsumoto Y, Suito H, Takahashi M, Sekino N, Komatsu A, Suzuki T, Matsubara H. Histone Demethylase LSD1 Inhibitors Prevent Cell Growth by Regulating Gene Expression in Esophageal Squamous Cell Carcinoma Cells. Ann Surg Oncol. 2016 Jan; 23(1):312-20. PMID: 25791791.
    Citations: 1     Fields:    Translation:HumansCells
  12. Ikuta S, Sekino N, Hara T, Saito Y, Chida K. Mouse epidermal keratinocytes in three-dimensional organotypic coculture with dermal fibroblasts form a stratified sheet resembling skin. Biosci Biotechnol Biochem. 2006 Nov; 70(11):2669-75. PMID: 17090939.
    Citations:    
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Sekino's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (76)
Explore
_
Co-Authors (1)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.